Loading...
Editors from NEJM Journal Watch Oncology and Hematology attended the recent meeting of the American Society of Hematology (ASH). Here, Dr. David Green describes the latest findings in benign hematology.
Chronic graft-versus-host disease (GvHD) often complicates unrelated donor transplantation and is usually managed with immunosuppressive drugs. To evaluate whether the addition of antithymocyte globulin (Thymoglobulin [TG]) to the pretransplant conditioning regimen improves outcomes after myeloablative or nonmyeloablative unrelated donor transplantation, Walker and colleagues conducted a multicenter, open-label, randomized controlled trial (abstract 38) in which 196 patient…